Synchronoss Announces Closing of $235 Million of Common Stock and Senior Notes Offerings

In addition, Synchronoss raised $75 million through a
private placement of preferred stock

Net proceeds used to refinance the company's capital structure

BRIDGEWATER, N.J. , June 30, 2021 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (NASDAQ: SNCR), a global leader and innovator of cloud, messaging and digital solutions, today announced that on June 29, 2021 it closed an underwritten public offering of 42,307,692 shares of common stock, which included 3,846,154 shares issued in connection with the underwriters' option to purchase additional shares, at a price to the public of $2.60 per share, for gross proceeds of approximately $110 million. The Company also announced that on June 30, 2021 it closed an underwritten public offering of $125 million aggregate principal amount of 8.375% senior notes due 2026, which included $5 million aggregate principal amount of senior notes issued in connection with the underwriters' option to purchase senior notes. Gross proceeds for both offerings are exclusive of underwriting discounts and commissions and estimated offering expenses payable by the Company.

Synchronoss and the senior notes both received a rating of BB– from Egan–Jones Ratings Company, an independent, unaffiliated rating agency. The notes are expected to begin trading on the Nasdaq Global Select Market under the symbol "SNCRL" as early as July 1, 2021.

In addition to the public offerings, on June 30, 2021 the Company closed a private placement of 75,000 shares of its Series B Perpetual Non–Convertible Preferred Stock to B. Riley Principal Investments, LLC for an aggregate purchase price of $75 million.

The two public offerings and the private placement resulted in net proceeds of approximately $300 million after deducting underwriting discounts and commissions, but before expenses. On June 30, 2021, the Company used the net proceeds in part to fully redeem all outstanding shares of its Series A Convertible Participating Perpetual Preferred Stock owned by an affiliate of Siris Capital Group and to repay amounts outstanding under the Company's revolving credit facility.

"Synchronoss has emerged from this comprehensive refinancing process with a solid financial foundation that will support our mission to empower our customers to connect with their subscribers in trusted and meaningful ways," said Jeff Miller, President and CEO of Synchronoss. "Today we have a sustainable financial environment that gives us the operating flexibility required to invest in delivering and enhancing great cloud, messaging and digital experiences for our customers; to enable long–term growth; and to deliver higher stockholder value to those who invest in the company."

The refinancing has also led to the departure of Synchronoss Board of Directors members Frank Baker, Peter Berger and Robert Aquilina, each of whom is associated with Siris Capital Group. "On behalf of the entire Board and management, I would like to thank Frank, Peter and Bob for their contributions to Synchronoss over the last three years and for their generosity as advisors to me personally," said Miller.

In conjunction with this new capitalization, B. Riley Financial, Inc., including certain of its affiliates, serve as Synchronoss' anchor investor. Synchronoss has granted B. Riley representation on its Board.

Bryant Riley, Chairman and Co–CEO of B. Riley Financial, Inc., commented: "We are pleased to serve as a strategic partner and financial sponsor to Synchronoss on this capitalization and are committed to leveraging the full operational and financial capabilities of our platform to support Synchronoss in its strategy to deliver value. We look forward to continuing to work closely with Jeff and the entire management team as Synchronoss enters this exciting new phase for its business."

B. Riley Securities, Inc., acted as the lead underwriter and sole book–running manager for the common stock offering. Northland Capital Markets acted as co–manager for the common stock offering.

B. Riley Securities, Inc. acted as the sole book–running manager for the senior notes offering. Northland Capital Markets, Aegis Capital Corp. and EF Hutton, a division of Benchmark Investments, LLC acted as lead managers for the senior notes offering.

The common stock and senior notes were offered under the Company's shelf registration statement on Form S–3, which was declared effective by the Securities and Exchange Commission ("SEC") on August 28, 2020. The offerings were made only by means of a prospectus supplement and accompanying base prospectus. Copies of the prospectus supplement and the accompanying base prospectus for the offering may be obtained on the SEC's website at, or by contacting B. Riley Securities by telephone at (703) 312–9580, or by email at

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, sale or solicitation would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Synchronoss

Synchronoss Technologies (NASDAQ: SNCR) builds software that empowers companies around the world to connect with their subscribers in trusted and meaningful ways. The company's collection of products helps streamline networks, simplify onboarding and engage subscribers to unleash new revenue streams, reduce costs and increase speed to market. Hundreds of millions of subscribers trust Synchronoss products to stay in sync with the people, services and content they love. That's why more than 1,500 talented Synchronoss employees worldwide strive each day to reimagine a world in sync. Learn more at

Safe Harbor Statement

This release contains forward–looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including but not limited to statements regarding the closing of the public offering and the anticipated use of the proceeds thereof. These forward–looking statements are subject to a number of risks, including the satisfaction of customary closing conditions related to the public offering and the risk factors set forth from time to time in Synchronoss' SEC filings, including but not limited to the risks that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections (as applicable) of Synchronoss' Annual Report on Form 10–K for the year ended December 31, 2020 and Quarterly Report on Form 10–Q for the period ended March 31, 2021, which are on file with the SEC and available on the SEC's website at In addition to the risks described above and in Synchronoss' other filings with the SEC, other unknown or unpredictable factors also could affect Synchronoss' results. No forward–looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Synchronoss undertakes no obligation to update any forward–looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.


Anais Merlin, CCgroup (International)
Diane Rose, CCgroup (North America)

Todd Kehrli/Joo–Hun Kim, MKR Investor Relations, Inc.

GLOBENEWSWIRE (Distribution ID 8273461)

The International Action Centre issues the following statement on: CAPE VERDE TAKES ON THE UNITED NATIONS

PRAIA, Cape Verde, June 30, 2021 (GLOBE NEWSWIRE) — In a decision on interim measures dated June 8, the United Nations Human Rights Committee called on Cape Verde to "refrain from extraditing Mr. Alex Saab to the United States of America" and to "take all necessary measures to ensure access to appropriate health care ["] by independent and specialized physicians of his choice". This decision ordering interim measures is the first urgent step resulting from the registration of a complaint filed by Alex Saab before United Nations Human Rights Committee.

In an interview on June 29, 2021, the Cape Verdean Prosecutor General, Mr Jose Luis Landim, makes a frontal attack on the United Nations, claiming that the UN Human Rights Committee does not have the competence to impose the suspension of the extradition of Alex Saab from Cape Verde to the United States of America.

Such a position is alarming and is a legal, strategic and ethical mistake.

First, this position is completely wrong in law. We would like to remind Mr Landim that Cape Verde has chosen to ratify the International Covenant on Civil and Political Rights since August 6, 1993 and the Optional Protocol to the International Covenant on Civil and Political Rights since May 19, 2000. It must therefore comply with its international obligations in good faith and fully respect the decisions of the expert body responsible for interpreting the International Covenant on Civil and Political Rights, the Human Rights Committee. Saying that the Committee does not have the power to request the suspension of an extradition that may expose someone to risks of irreparable harms and of violations of the right to life and right of physical integrity, is an unforgivable legal error totally incompatible with the rule of law.

Second, such a position is a frontal attack on the United Nations and the human rights that are at the heart of the values that the Organization defends. It sends a clear message to the world that Cape Verde can exercise its sovereignty to violate human rights while ignoring the norms of international human rights law to which it has subscribed and ignoring international decisions. In doing so, Cape Verde, after defying the ECOWAS Court of Justice which ordered it to release the arbitrarily detained Alex Saab, after violating Alex Saab's diplomatic immunity as a Special Envoy and an Ambassador to the African Union, is taking a hostile stance towards the United Nations and placing itself on the outside of the international community.

Third, such a position is a mistake in terms of fundamental ethical values. By requesting the suspension of Alex Saab's extradition pending the examination of the merits of the case, the Human Rights Committee was inviting Cape Verde to show humanity and common sense by considering that the extradition would be detrimental to the physical integrity and life of Alex Saab. The Committee did not take a political position, but a purely humanitarian one.

MEDIA Contact:
Sara Flounders
International Action Center
Tel: +1 212–633–6646

GLOBENEWSWIRE (Distribution ID 8273384)

Survey Projects Demand for Business School Graduates to Rebound in Post-Pandemic Era

RESTON, Va., June 30, 2021 (GLOBE NEWSWIRE) — The Graduate Management Admission Council (GMAC), a global association of leading graduate business schools, today released its annual 2021 Corporate Recruiters Survey. The report found that corporate recruiters project a robust demand for business school graduates, with nine in ten of them expecting it to increase or remain stable in the next five years. In addition, a higher proportion of recruiters in 2021 (37%) expect the demand to increase than that in the previous year (30%), with more than half of the European recruiters (54%) sharing such a view compared to their Asian (32%) and American (34%) counterparts.

"In a little more than a decade, the proportion of surveyed recruiters planning to hire MBA graduates has grown significantly, a trend especially notable in Europe, where the percentage jumped from 44 percent in 2010 to nearly twice as much (86%) in 2021, and in the United States, where it grew from 56 percent to 94 percent, a 68 percent increase," said Sangeet Chowfla, president and CEO of GMAC. "As corporations recover from the pandemic and rebuild their workforces, it is no surprise that business school graduates " with their leadership and managerial skills in high demand " are specially strengthened in their value proposition as an employee and uniquely positioned to meet today's economic challenges."

Key Findings

MBA salary and hiring are expected to return to pre–pandemic levels

In 2020, the projected MBA median salary reached an all–time high of $115,000 before COVID–19 severely disrupted the global economy and caused it to drop down to $105,000 three months into the pandemic. However, the median MBA salary for 2021 is projected to recover to its pre–pandemic 2020 level of $115,000. At this rate, the median salary of MBA graduates is 77 percent more than those with a bachelor's degree ($65,000) and 53 percent higher as compared to those hired directly from industry ($75,000). This salary premium shows that investing in an MBA credential continues to pay off over the time, helping an MBA graduate earn $3 million more in his or her lifetime than someone holding only a bachelor's degree. GMAC's own offers a helpful tool to calculate the return of investment (ROI) for business school graduates.

Before the pandemic, 92 percent of recruiters indicated they were planning to hire MBA graduates in 2020. However, the disruptions caused by COVID–19 adversely affected those plans, and hence the actual hiring of MBA graduates (80%) was lower than 2020 projections. Looking ahead, the proportion of recruiters planning to hire MBAs in 2021 (91%) returns to the same level as pre–pandemic 2020 (92%). The MBA hiring projections exhibit strength across key regions and industries. Specifically, 95 percent of the recruiters in the consulting sector, an industry in most demand by MBA graduates, are projecting to hire them""a reversal from the 2020 actual hiring of 76%.

Technology sector embraces MBA graduates for hiring and promotion

According to survey respondents, demand for MBA graduates by the technology industry is anticipated to increase by 10 percentage points in 2021 compared to pre–pandemic 2020. In fact, with 96 percent of tech recruiters projecting to hire MBA graduates in 2021, the demand for MBA talents tops the previous three years. The data also show that two in three (68%) recruiters in the technology sector agree that leaders in their organizations tend to have a graduate business school education""an increase of 11 percentage points from 2020 (57%).

"Technology companies are placing a high value on leaders who are not just technically skilled, but also have strong strategic, interpersonal, communication and decision–making skills, as well as an understanding of the importance of diversity and inclusion and sustainability in their organizations – these will be critical to driving organizational growth and innovation,” said Peter Johnson, Assistant Dean of UC Berkeley's Haas School of Business. “These core skills represent the signature business schools are imbuing in graduates from their MBA and business master's programs."

Perceptions of online programs are mixed depending on region, sector

Online programs have been gaining traction in recent years. According to GMAC data, 50 more online MBA programs accepted GMAT scores in the testing year (TY) 2020 as compared to five years earlier in TY 2016. In addition, 84 percent of online MBA programs reported an increase in applications in GMAC's 2020 Application Trends Survey.

However, when corporate recruiters were asked about their level of agreement with the statement "My organization values graduates of online and in–person programs equally," only one–third (34%) of them agreed. In terms of industries, recruiters from the finance and accounting industry (41%) are more likely to view graduates of online programs as equal to their on–campus peers, compared to their recruiting counterparts in consulting (25%) or technology (28%). As online programs are clearly a fast–growing area of graduate management education, the sustainability of demand will require a higher level of acceptance by employers, particularly when GMAC's latest candidate research suggests a similar disparity in terms of perception of online versus in–person programs.

"As business schools continue to evolve modalities and more candidates are able to access MBA and business master's programs through online delivery, this presents the graduate management education community with an opportunity to align expectations and outcomes for graduates and corporate recruiters," said Chowfla.

About the Survey

GMAC has been conducting the Corporate Recruiter Survey on behalf of the graduate management education community since 2001. This year's survey, administered in partnership with the Association of MBAs (AMBA), the European Foundation for Management Development (EFMD), MBA Career Services & Employer Alliance (MBA CSEA), and career services offices at participating graduate business schools worldwide, received 529 responses between February 25 – March 31, 2021. More details of the full report, and other research series produced by GMAC, are available on

About GMAC

The Graduate Management Admission Council (GMAC) is a mission–driven association of leading graduate business schools worldwide. Founded in 1953, GMAC creates solutions and experiences that enable business schools and candidates to better discover, evaluate, and connect with each other.

GMAC provides world–class research, industry conferences, recruiting tools, and assessments for the graduate management education industry, as well as tools, resources, events, and services that help guide candidates through their higher education journey. Owned and administered by GMAC, the Graduate Management Admission Test (GMAT) exam is the most widely used graduate business school assessment.

GMAC also owns and administers the NMAT by GMAC (NMAT) exam and the Executive Assessment (EA). More than 7 million candidates on their business master's or MBA journey visited GMAC's last year to explore business school options, prepare and register for exams, and get advice on the admissions process. BusinessBecause and The MBA Tour are subsidiaries of GMAC, a global organization with offices in China, India, the United Kingdom, and the United States.

To learn more about our work, please visit

Media Contact:

Teresa Hsu
Sr. Manager, Media Relations
202–390–4180 (mobile)

GLOBENEWSWIRE (Distribution ID 8272612)

CasperLabs & SJM Group Partner to Promote Web3 Adoption in the United Arab Emirates

DUBAI, United Arab Emirates, June 30, 2021 (GLOBE NEWSWIRE) — Today, CasperLabs, a leading blockchain services company and developer of the Casper Network, announced a partnership with His Highness Sheikh Juma bin Maktoum Al Maktoum's SJM Group of Companies to establish their local presence to facilitate use for the Casper Network in the UAE.

In tandem with Lead Ventures, CasperLabs will work closely with local government agencies and UAE–based enterprises to conceptualize, develop and implement innovative use cases that leverage Casper's unique combination of enterprise–grade security, scalability and decentralization.

The partnership is the latest milestone in CasperLabs' expanding presence in the Middle East and North Africa (MENA), and comes on the heels of Saeed Hareb Al Darmaki's appointment as Managing Director, MENA for CasperLabs. CasperLabs first entered into the region earlier this year through a strategic partnership with Lead Ventures and the endorsement from His Highness will further drive momentum in the market.

Since its mainnet launch this spring, Casper has emerged as the only true enterprise grade blockchain on the market, offering a compelling alternative to networks that have failed to garner adoption for enterprise use cases. A growing number of organizations are building on Casper, citing its more predictable and cost–effective gas pricing, ease of migration for existing apps/dapps, the more environmentally–friendly energy consumption model and CasperLabs' whiteglove support and services as primary factors for choosing to build on the network.

Known globally for its spirit of innovation, the UAE is exploring building on Casper for various use cases such as financial services; proven authenticity and sourcing for the Dubai Gold and Commodities Exchange; creation of a national UAE identity solution; certificate, registry and notary signing using a dapp like CasperSign; and university credential verification, to name a few.

"Our Group's vision is aligned with the initiatives of the UAE Government and the regional companies who have consistently accepted and implemented newer technologies in their daily needs. We are pleased to have CasperLabs partner with us to bring its expertise to develop further growth in these sectors," said HH Sheikh Juma Bin Maktoum Al Maktoum, Chairman SJM Group of Companies.

"CasperLabs is honored to be partnering with His Highness' SJM Group of Companies and the UAE on government initiatives. We have seen a remarkable demand for Web3 solutions in this region and we are excited to finally be able to deliver a network that meets the needs for a robust enterprise network. We are honored to be building out the Casper ecosystem in the region with the support of a visionary leader," said Mrinal Manohar, CEO & CoFounder CasperLabs.

About CasperLabs
CasperLabs provides professional services and support for organizations building on the Casper network. Guided by open source principles, CasperLabs is committed to supporting the next wave of blockchain adoption among businesses and providing developers with a reliable and secure framework to build private, public and hybrid blockchain applications. Its team possesses deep enterprise technology experience, hailing from organizations including Google, Adobe, AWS, Dropbox and Microsoft.

To learn more, visit

Media Contact
Kara Miley

GLOBENEWSWIRE (Distribution ID 8272679)

Zoom to Acquire Kites GmbH

SAN JOSE, Calif. and KARLSRUHE, Germany, June 29, 2021 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ: ZM) today announced it has signed a definitive agreement to acquire Karlsruhe Information Technology Solutions – Kites GmbH ("Kites"), a start–up dedicated to developing real–time Machine Translation ("MT") solutions. The terms of the transaction were not disclosed.

Kites was founded in 2015 and has academic roots with Karlsruhe Institute of Technology, where co–founders Dr. Alex Waibel and Dr. Sebastian Stker are faculty members. Kites' talented team of 12 research scientists will help Zoom's engineering team advance the field of MT to improve meeting productivity and efficiency by providing multi–language translation capabilities for Zoom users.

"We are continuously looking for new ways to deliver happiness to our users and improve meeting productivity, and MT solutions will be key in enhancing our platform for Zoom customers across the globe," said Velchamy Sankarlingam, President of Product and Engineering at Zoom. "With our aligned missions to make collaboration frictionless "" regardless of language, geographic location, or other barriers "" we are confident Kites' impressive team will fit right in with Zoom."

"Kites emerged with the mission of breaking down language barriers and making seamless cross–language interaction a reality of everyday life, and we have long admired Zoom for its ability to easily connect people across the world," said Dr. Waibel and Dr. Stker. "We know Zoom is the best partner for Kites to help advance our mission and we are excited to see what comes next under Zoom's incredible innovation engine."

Dr. Stker and the rest of the Kites team will remain based in Karlsruhe, Germany, where Zoom looks forward to investing in growing the team. Zoom is exploring opening an R&D center in Germany in the future. Dr. Waibel will become a Zoom Research Fellow, a role in which he will advise on Zoom's MT research and development.

Forward–Looking Statements
This press release contains express and implied "forward–looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 related to Zoom's acquisition of Kites that involves substantial risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed or implied by such statements. Forward–looking statements in this communication include, among other things, statements about the potential benefits of the transaction, our development of our MT solutions, our ability to integrate the Kites team, and potential growth opportunities. In some cases, you can identify forward–looking statements by terms such as "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "project," "will," "would," "should," "could," "can," "predict," "potential," "target," "explore," "continue," or the negative of these terms, and similar expressions intended to identify forward–looking statements. However, not all forward–looking statements contain these identifying words. By their nature, these statements are subject to numerous uncertainties and risks, including factors beyond our control, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. These assumptions, uncertainties and risks include that, among others, the possibility that the anticipated benefits of the transaction are not realized when expected or at all, division of management's attention from ongoing business operations and opportunities, potential adverse reactions or changes to business or employee relationships, the ability to integrate Kites successfully, and other factors that may affect future results of Zoom. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward–looking statements are included under the caption "Risk Factors" and elsewhere in our most recent filings with the Securities and Exchange Commission (the "SEC"), including our quarterly report on Form 10–Q for the quarter ended April 30, 2021. Forward–looking statements speak only as of the date the statements are made and are based on information available to Zoom at the time those statements are made and/or management's good faith belief as of that time with respect to future events. Zoom assumes no obligation to update forward–looking statements to reflect events or circumstances after the date they were made, except as required by law.

About Zoom
Zoom is for you. We help you express ideas, connect to others, and build toward a future limited only by your imagination. Our frictionless communications platform is the only one that started with video as its foundation, and we have set the standard for innovation ever since. That is why we are an intuitive, scalable, and secure choice for individuals, small businesses, and large enterprises alike. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Visit and follow @zoom.

About Kites
Karlsruhe Information Technology Solutions "" Kites GmbH is a start–up company founded in 2015 by Dr. Sebastian Stker and Dr. Alex Waibel with the express purpose of transforming the latest research in speech translation technology into viable products. Kites' mission is breaking down language barriers and making seamless cross–language interaction a reality of everyday life. Kites aims to provide custom services to its customers in order to provide technology and services that fit and are operated and maintained at the necessary quality levels.

Zoom Press Relations
Colleen Rodriguez
Global Media Relations Lead

Zoom Investor Relations
Tom McCallum
Head of Investor Relations

GLOBENEWSWIRE (Distribution ID 8272061)

Nikkiso Clean Energy & Industrial Gases Group Announces Formation of Nikkiso Clean Energy & Industrial Gases (SEA) Sdn. Bhd in Malaysia

TEMECULA, Calif., June 29, 2021 (GLOBE NEWSWIRE) — Nikkiso Clean Energy & Industrial Gases Group (Group), a subsidiary of Nikkiso Co., Ltd (Japan), is proud to announce the creation of Nikkiso Clean Energy & Industrial Gases (SEA) Sdn. Bhd. effective 1st July 2021. This company represents the combining of our two Malaysia business units: Cryogenic Industries and Cryoquip in a new joint facility.

This merger represents another step forward in the Group's overall corporate growth strategy, emphasizing their ability to provide both global and regional support for sales and service. The name change emphasizes the support and strength of the larger Group; Clean Energy is the growth engine and Industrial Gases the core foundation.

The new, larger facility provides a strong support structure for future growth. Ideally placed within the region to support their key customers and provide an additional focus on clean energy, the 56,400 square foot facility is twice the size of their previous center. It has an improved capacity for loading flow and manufacturing for vaporizers, vacuum lines, process skid fabrication and assembly, refurbishment work, as well as pumps parts and service. In addition, it offers opportunities for sharing resources with other Nikkiso group companies (supporting Nikkiso Cryo or for fabrication of LEWA SEA and/or Geveke Malaysia skids).

According to Tim Born, the Vice President of Nikkiso CE&IG for South East Asia and Oceania;

"This new facility will provide a one–stop shop for the Nikkiso CE&IG Group's cryogenic process equipment, installations and services. The amalgamation of our two businesses in Malaysia and the willingness to expand our facility and capabilities highlights our Group's commitment to this region. Our new facility will provide timely local support for our complete range of products and services, and I look forward to working together with our customers and our talented local Nikkiso CE&IG team to provide the products and services this growing region needs."

Nikkiso CE&IG (SEA) is responsible for business in South East Asia, namely Malaysia, Singapore, Thailand, Indonesia, Philippines, Myanmar, Vietnam, Brunei, Laos and Cambodia, as well as Taiwan, Bangladesh and Pakistan, and provides support to the Middle East, India, Africa and Australia.

Contact Information:

Nikkiso Clean Energy and Industrial Gases (SEA) Sdn. Bhd. 199601016333
(formerly known as Cryoquip Sdn. Bhd. 388684–P)
Lot 862, Jalan Subang 8, Taman Perindustrian Subang
47600 Subang, Selangor, Malaysia

Tel: +60 3 8081 8330
Fax: +60 3 8081 8360
Email: Website:

Cryogenic Industries, Inc. (now a member of Nikkiso Co., Ltd.) member companies manufacture engineered cryogenic gas processing equipment and small–scale process plants for the liquefied natural gas (LNG), well services and industrial gas industries. Founded over 50 years ago, Cryogenic Industries is the parent company of ACD, Cosmodyne and Cryoquip and a commonly–controlled group of approximately 20 operating entities.

For more information, please visit and

Anna Quigley

GLOBENEWSWIRE (Distribution ID 8271851)

Entera Bio to Conduct Conference Call on June 30 to Discuss Phase 2 Results for EB613 Positioned to be the First Oral Bone-Building Agent for the Treatment of Osteoporosis

BOSTON and JERUSALEM, June 28, 2021 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced it will conduct a conference call to discuss results from its successfully completed Phase 2 clinical trial of EB613 for the treatment of osteoporosis. EB613 is an oral formulation of human parathyroid hormone (1–34), or PTH, and is positioned to be the first oral bone building (anabolic) product to treat osteoporosis patients.

Attendees on the call will include osteoporosis expert and Principal Investigator of the Phase 2 study Dr. Liana Tripto–Shkolnik, Sheba Medical Center, Institute of Endocrinology. Dr. Tripto–Shkolnik will provide context on the results of the study and the benefits of an oral drug to treat osteoporosis. Also on the call will be Entera CEO, Spiros Jamas; President of R&D, Phillip Schwartz; Chief Medical Officer, Art Santora; and CFO, Ramesh Ratan.

The conference call will take place on Wednesday, June 30, 2021 from 12–1pm EDT and will include a question–and–answer session. To participate on the live call, please dial (844) 467–6041 (US) or (409) 217–8787 (international) and provide the conference ID "5298499" five to ten minutes before the start of the call.

To access a live audio webcast of the presentation on the "Investor Relations" page of Entera's website, please click here. A replay of the webcast will be archived on Entera's website for approximately 45 days following the presentation.

About Entera Bio

Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company's proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company's most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. For more information on Entera Bio, visit

Forward Looking Statements

Various statements in this release are "forward–looking statements" under the securities laws. Words such as, but not limited to, "anticipate," "believe," "can," "could," "expect," "estimate," "design," "goal," "intend," "may," "might," "objective," "plan," "predict," "project," "target," "likely," "should," "will," and "would," or the negative of these terms and similar expressions or words, identify forward–looking statements. Forward–looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward–looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved.

Important factors that could cause actual results to differ materially from those reflected in Entera's forward–looking statements include, among others: changes in our interpretation of the complete3–month biomarker data from the ongoing Phase 2 clinical trial of EB613, the timing of data readouts from the ongoing Phase 2 clinical trial of EB613, the full results of the Phase 2 clinical trial of EB613, which is still ongoing and our analysis of those full results, the FDA's interpretation and review of our results from and analysis of our Phase 2 trial of EB613, unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; a possible suspension of the Phase 2 clinical trial of EB613 for clinical or data–related reasons; the impact of COVID–19 on Entera's business operations including the ability to collect the necessary data from the Phase 2 trial of EB613; the potential disruption and delay of manufacturing supply chains, loss of available workforce resources, either by Entera or its collaboration and laboratory partners, due to travel restrictions, lay–offs or forced closures or repurposing of hospital facilities; impacts to research and development or clinical activities that Entera is contractually obligated to provide, such as those pursuant to Entera's agreement with Amgen; overall regulatory timelines, if the FDA or other authorities are closed for prolonged periods, choose to allocate resources to review of COVID–19 related drugs or believe that the amount of Phase 2 clinical data collected are insufficient to initiate a Phase 3 trial, or a meaningful deterioration of the current political, legal and regulatory situation in Israel or the United States; the availability, quality and timing of the data from the Phase 2 clinical trial of EB613 in osteoporosis patients; the ability to find a dose that demonstrates the comparability of EB613 to FORTEO in the ongoing Phase 2 clinical trial of EB613; the size and growth of the potential market for EB613 and Entera's other product candidates including any possible expansion of the market if an orally delivered option is available in addition to an injectable formulation; the scope, progress and costs of developing Entera's product candidates including EB612 and GLP–2; Entera's reliance on third parties to conduct its clinical trials; Entera's expectations regarding licensing, business transactions and strategic collaborations; Entera's operation as a development stage company with limited operating history; Entera's ability to continue as a going concern absent access to sources of liquidity; Entera's expectations regarding its expenses, revenue, cash resources, liquidity and financial condition; Entera's ability to raise additional capital; Entera's interpretation of FDA feedback and guidance and how such guidance may impact its clinical development plans; Entera's ability to obtain and maintain regulatory approval for any of its product candidates; Entera's ability to comply with Nasdaq's minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States; Entera's intellectual property position and its ability to protect its intellectual property; and other factors that are described in the "Special Note Regarding Forward–Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Entera's annual and current filings which are on file with the SEC and available free of charge on the SEC's website at Additional factors may be set forth in those sections of Entera's Annual Report on Form 20–F for the year ended December 31, 2020, filed with the SEC in the first quarter of 2021. In addition to the risks described above and in Entera's annual report on Form 20–F and current reports on Form 6–K and other filings with the SEC, other unknown or unpredictable factors also could affect Entera's results. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated in such forward–looking statements and estimates will be achieved.

All written and verbal forward–looking statements attributable to Entera or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Entera cautions investors not to rely too heavily on the forward–looking statements Entera makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Entera undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward–looking statements, whether as a result of new information, future events or otherwise.

GLOBENEWSWIRE (Distribution ID 8271666)

The Globe and Mail’s Wins Digiday Media Award

TORONTO, June 28, 2021 (GLOBE NEWSWIRE) —, The Globe and Mail's artificial intelligence–based automation and prediction engine, won the 2021 Digiday Media Award for Best Publisher Platform, which recognizes technology that is most successful in helping publishers achieve their goals.

"AI is an essential technology for helping publishers add authentic value to stories "" extending their measure of success beyond page views and virality. For example, Sophi is able to provide data on how much each article on The Globe and Mail contributes to subscriber retention, acquisition, registration potential and advertising dollars. Additionally, to effectively deploy machine learning, around 10% of The Globe and Mail's workforce is now data scientists and engineers, hired to develop Sophi and grow the strategy even further," Digiday said.

The awards honour companies, technologies and campaigns that have stood out throughout the media over the past year. "This year, the competition was fierce and the programs robust. Innovation and big ideas expanded the playing field for many of the winners, even in a year when quarantines limited where and how people could work "" and play," according to Digiday.

Phillip Crawley, Publisher and CEO of The Globe and Mail, commented: "It's an honour to be chosen as the winner of Digiday's Media Award for Best Publisher Platform. We aren't often up against companies in both the media and marketing industries but our investments in Sophi have been driven by the understanding that our technology can directly drive performance and economic growth for companies across a large range of industries."

The other finalists in the Best Publisher Platform category were: Piano, Connatix, Insticator, Duration Media and Adapex LLC.

Sophi is an artificial–intelligence system that helps publishers identify and leverage their most valuable content. It has powerful predictive capabilities "" using natural language processing, Sophi Dynamic Paywall is a fully dynamic, real–time, personalized paywall engine that analyses both content and user behaviour to determine when to ask a reader for money or an email address, and when to leave them alone.

Sophi Site Automation autonomously curates digital content to find and promote the most valuable articles. It places 99% of the content on all of The Globe and Mail's digital pages, including its homepage and section pages. Sophi has been so successful that it is now being used for print laydown as well. Sophi is available to publishers across the globe to enable their content producers to focus on creating the best content possible.

Earlier this month, Sophi won the 2021 International News Media Association (INMA) Global Media Awards for Best in Show in North America and Best Use of Data to Automate or Personalize. Sophi has also won the Online Journalism Award (OJA) for Technical Innovation in the Service of Digital Journalism, handed out by the Online News Association (ONA), and both the World Digital Media Award and the North American Digital Media Award awarded by The World Association of News Publishers (WAN–IFRA) in the category of Best Digital News Start–up.

About ( is a suite of AI–powered optimization and prediction tools that helps content publishers make important strategic and tactical decisions. Sophi solutions range from Sophi Site Automation and Sophi for Paywalls to Sophi Analytics, a decision–support system for content publishers. Sophi is designed to improve the metrics that matter most to any business, such as subscriber retention and acquisition, engagement, recency, frequency and volume.

GLOBENEWSWIRE (Distribution ID 8271636)

Sol-Gel Announces Pipeline Update and Future Development Plans

  • Sol–Gel investigational SGT–510 was found to be more effective than roflumilast cream, 0.3%, in a human xenograft psoriasis animal model

  • Sol–Gel is developing tapinarof cream, 1%, aiming to offer product formulation innovations and increased affordability for patients compared to the brand expected to be launched
  • Our proof–of–concept study for SGT–210 (erlotinib gel) in palmoplantar keratoderma patients has been completed and indicated a possible modest improvement

  • Sol–Gel to host Conference Call today at 8:00 am U.S. EDT to discuss the data and provide a corporate update

NESS ZIONA, Israel, June 28, 2021 (GLOBE NEWSWIRE) — Sol–Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical–stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced positive pre–clinical data for SGT–510, its investigational topical roflumilast drug candidate and provided a corporate update.

The study was conducted at the Skin Research Laboratory, Rappaport Faculty of Medicine, Technion Institute of Technology, Haifa, Israel, under the supervision of Professor Amos Gilhar, M.D. Professor Gilhar has pioneered a human psoriasis xenograft mouse model, consisting of immunodeficient mice transplanted with healthy human skin, and used it to validate a number of approved topical and systemic dermatology products, including those sold by large pharmaceutical companies. For the study, the human xenograft animal model was induced with psoriasis by injection of activated allogeneic IL2–enriched peripheral blood mononuclear cells isolated from psoriatic patients. The mice were then treated with several topical agents and assessed for recovery after each intervention.

“Our model has been proven to predict efficacy for novel approaches in the treatment of psoriasis, providing very valuable information to the companies leveraging this assay," commented Professor Gilhar.

All tested articles were applied for 14 days either once or twice daily:

  • Nine (9) out of 10 animals fully recovered following a twice–daily application of dexamethasone (the positive control);
  • None (0) out of 10 recovered following a once–daily application of vehicle cream (the negative control);
  • Three (3) out of 10 animals recovered following a once–daily application of roflumilast cream, 0.3% that was formulated by Sol–Gel according to conventional methods of cream formulation;
  • Six (6) out of 10 animals fully recovered following once–daily application of SGT–510.

Based on these results, Sol–Gel filed a provisional patent application for its novel and non–obvious formulation of SGT–510. By the end of 2022, the Company expects to have head–to–head data against a formulation of roflumilast cream, 0.3% and expects to initiate Phase 2 work thereafter.

Mr. Mori Arkin, Executive Chairman of the Board of Sol–Gel, commented, "While this small study does not represent a formal statistical analysis, we are very pleased that these early–stage results, demonstrating 60% recovery after a once–daily application of SGT–510 in the human psoriasis xenograft mouse model, supported our predefined hypothesis and confirmed our expectations about formulation superiority using our approach. Given our expertise in formulation science and topical drug delivery, we believe that we have an advantage due to the patentability of SGT–510. It is our belief that if these results are corroborated by clinical studies, a patent, if granted, will provide us not only freedom to operate, but more importantly, intellectual property protection against generic entrants until expiry of our patent in 2040."

Mr. Arkin continued, "Due to the safety–limiting features of steroids, the prospect of an effective alternative to steroid medicine for the treatment of psoriasis, such as SGT–510, is significant and would fill a critical unmet need for these patients. Sol–Gel intends to develop SGT–510 in accordance with the 505(b)(2) regulatory pathway by only referencing the oral roflumilast brand DALIRESP . The rationale for this carefully planned regulatory strategy is to create a clear path to market, with no litigation requirement. We expect that all Orange Book–listed DALIRESP patents will have expired by the time of its New Drug Application (NDA) submission, and that no Paragraph IV certification with a consequent 30–month stay would be required. As we plan to develop more than one roflumilast product, including potential combination products, we may also utilize alternative regulatory strategies. Our deep involvement in topical generics along with the supportive view of independent intellectual property experts guides us to believe that there is a significant risk that present patents and patent applications for roflumilast 0.3% cream may be unable to prevent early genericization of the roflumilast products currently under development. Should this be the case, our innovative formulations of roflumilast, if approved by the FDA, would give us the opportunity to become a leading player in the multi–billion–dollar psoriasis and atopic dermatitis markets in the second half of the decade."

Mr. Arkin added, "Separately, we have made progress towards the development of our proprietary formulation of tapinarof cream, 1%, SGT–310. We plan to pursue a de–novo NDA via the 505(b)(1) regulatory pathway, with the goal of creating a second alternative to an investigational tapinarof cream, 1%, for which an NDA was already submitted to the FDA. According to this strategy, we plan to launch our tapinarof drug product worldwide no later than five years following the U.S. approval of the first tapinarof cream, aiming to increase affordability for patients compared to the brand expected to be launched. In addition, we intend to differentiate ourselves by offering tapinarof product formulation innovations for new indications. We have already been refining our strategy in line with best regulatory practices, and our drug product will be developed via our active pharmaceutical ingredient (API) manufacturing collaboration with Wavelength Pharmaceuticals, previously known as Perrigo API, a company with an impressive track record of FDA GMP compliance."

Mr. Arkin further added: "Our proof–of–concept (POC) study for SGT–210 (erlotinib gel) in six (6) palmoplantar keratoderma (PPK) patients has been completed and indicated modest improvement and a favorable safety profile. In this study, we used a very low concentration of erlotinib. We are now planning to test erlotinib at much higher concentrations in an animal model in the second half of 2021 and if successful, will conduct a second POC study on PPK patients in 2022. We remain optimistic about this program."

Management to Host Conference Call Today

Sol–Gel will host an investor conference call today at 8 AM U.S. EDT to discuss today's announcement, herein, and the strategy of the company following today's partnership news, announced separately.

To participate in the call, dial either the domestic or international number fifteen minutes before the conference call begins:

Domestic: 1–877–407–0784
International: 1–201–689–8560
Passcode: 13720829

The live conference call and replay can also be accessed by audio webcast here and also on the Investor Relations section of the Company's website, located at https://ir.sol––relations.

About Roflumilast

Roflumilast is a selective, long–acting inhibitor of Phosphodiesterase–4 (PDE4). It is the active ingredient in the Food and Drug Administration (FDA) approved medication, DALIRESP , which is as an oral treatment indicated in the U.S. as a therapy to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.

A roflumilast cream 0.3% formulation is under investigation as a once–daily treatment of plaque psoriasis and positive Phase 3 results were recently reported.

About Tapinarof

Tapinarof is a novel, first–in–class, small–molecule topical therapeutic aryl hydrocarbon receptor (AhR)""modulating agent. It is in clinical development for the treatment of psoriasis and atopic dermatitis. The efficacy of tapinarof in psoriasis is attributed to its specific binding and activation of AhR, a ligand–dependent transcription factor, leading to the downregulation of proinflammatory cytokines, including interleukin 17, and regulation of skin barrier protein expression to promote skin barrier normalization.

About Erlotinib

Erlotinib is a tyrosine kinase receptor inhibitor which acts on the Epidermal Growth Factor Receptor (EGFR). It is the active pharmaceutical ingredient (API) in Tarceva which is used to orally treat non–small cell lung cancer, pancreatic cancer and several other types of cancer. Currently, there are no topical products of erlotinib, and erlotinib is not approved for plaque psoriasis.

About Wavelength Pharmaceuticals

Wavelength is a customer–focused backward–integrated world–class developer and manufacturer of Active Pharmaceutical Ingredients (APIs). It is the independent company of choice for pharmaceutical industry leaders that require advanced API solutions and reliable supply to gain sustainable competitive advantage. The company is on the same wavelength as its customers "" a partner in tune with the results required to best support their needs. Founded in Israel in 1987, with more than 280 customers in 50 countries, Wavelength produces more than 630 metric tons of commercial products every year, across a wide range of technologies including injectables, inhalables, highly potent, cytotoxic and controlled substances. Its cGMP–compliant facility is a first–class operation recognized for excellence in safety and environmental stewardship. Wavelength has achieved an exceptional track record for more than 30 years with all leading global regulatory authorities, including USFDA, EU–EMA, PMDA, TGA, KFDA, ANVISA and COFEPRIS. The company includes experts in complex chemistry, process development and scale–up, enzymatic reactions, crystalline forms and particle design, spray drying and other bioavailability–enhancing solutions. Wavelength offers end–to–end customized solutions to meet individual customer requirements, including full–spectrum API CDMO services from pre–clinical grams to multi–ton commercial scale "" always with uncompromising consistent quality, regulatory compliance and exceptional customer service.

About Sol–Gel Technologies

Sol–Gel is a clinical–stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol–Gel leverages its proprietary microencapsulation technology platform for the development of TWYNEO under investigation for the treatment of acne vulgaris with an NDA filed with the FDA and a PDUFA goal date set for August 1, 2021; and EPSOLAY , under investigation for the treatment of inflammatory lesions of rosacea with an NDA filed with the FDA and a PDUFA goal date set for April 26, 2021. Both product candidates are exclusively licensed for U.S. commercialization with Galderma Holding SA. Action on the NDA for EPSOLAY has not yet been taken due to the inability of the FDA to conduct a pre–approval inspection of the production site of EPSOLAY as a result of COVID–19 travel restrictions. The Company's pipeline also includes SGT–210, an early–stage topical epidermal growth factor receptor inhibitor, erlotinib, under investigation for the treatment of palmoplantar keratoderma, and preclinical assets tapinarof and roflumilast. For additional information, please visit www.sol–

Forward–Looking Statements

This press release contains "forward–looking statements" within the meaning Securities of the Private Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward–looking statements. These forward–looking statements include information about possible or assumed future results of our business, financial condition, results of operations, liquidity, plans and objectives. In some cases, you can identify forward–looking statements by terminology such as "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," "predict," "potential," or the negative of these terms or other similar expressions, including statements regarding the timing for the initiation of a Phase I study for SGT–510, the intellectual property protection that would be provided by a patent for SGT–210, the anticipated status of patents at the time of an NDA submission for SGT–210, the timing of the launch of our tapinarof drug product and the timing of a test of erlotinib with a much higher concentrations in an animal model and a second POC study on PPK patients. Forward–looking statements are based on information we have when those statements are made or our management's current expectation and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward–looking statements. Important factors that could cause such differences include, but are not limited to, the risk of a delay in receipt of approval, if any, of the NDA for TWNYEO, the risk of a further delay in receipt of approval, if any, of the NDA for EPSOLAY, the risk of a delay in the initiation of a Phase I study for SGT–510, the risk that a patent for SGT–210 will not provide the anticipated intellectual property protection, the risk that all Orange Book–listed DALIRESP patents will not have expired by the time of our NDA application for SGT–21 and that a consequent 30–month stay will required, the risk of a delay in the launch of our tapinarof drug product, the risk of a delay the timing of a test of erlotinib with a much higher concentrations in an animal model and the risk of a delay in a second POC study on PPK patients, risks relating to the effects of COVID–19 (coronavirus) as well as the following factors: (i) the adequacy of our financial and other resources, particularly in light of our history of recurring losses and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives; (ii) our ability to complete the development of our product candidates; (iii) our ability to find suitable co–development partners; (iv) our ability to obtain and maintain regulatory approvals for our product candidates in our target markets, the potential delay in receiving such regulatory approvals and the possibility of adverse regulatory or legal actions relating to our product candidates even if regulatory approval is obtained; (v) our ability to commercialize our pharmaceutical product candidates; (vi) our ability to obtain and maintain adequate protection of our intellectual property; (vii) our ability to manufacture our product candidates in commercial quantities, at an adequate quality or at an acceptable cost; (viii) our ability to establish adequate sales, marketing and distribution channels; (ix) acceptance of our product candidates by healthcare professionals and patients; (x) the possibility that we may face third–party claims of intellectual property infringement; (xi) the timing and results of clinical trials that we may conduct or that our competitors and others may conduct relating to our or their products; (xii) intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; (xiii) potential product liability claims; (xiv) potential adverse federal, state and local government regulation in the United States, Europe or Israel; and (xv) loss or retirement of key executives and research scientists. These and other important factors discussed in the Company's Annual Report on Form 20–F filed with the Securities and Exchange Commission ("SEC") on March 4, 2021 and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward–looking statements made in this press release. Any such forward–looking statements represent management's estimates as of the date of this press release. Except as required by law, we undertake no obligation to update publicly any forward–looking statements after the date of this press release to conform these statements.

For further information, please contact:

Sol–Gel Technologies

Gilad Mamlok
Chief Financial Officer

Investor relations
Irina Koffler
LifeSci Advisors

GLOBENEWSWIRE (Distribution ID 8271138)

SAFR® from RealNetworks Receives Axis Awards for Best Ecosystem Partner in the Middle East and in Africa

Seattle, WA, June 27, 2021 (GLOBE NEWSWIRE) — SAFR from RealNetworks, Inc. (NASDAQ: RNWK) ), a leader in high accuracy, low bias facial recognition, is pleased to announce that Axis Communications, a global leader in network video and surveillance products, has chosen SAFR as Best Ecosystem Partner 2020 for both the Middle East, and for Africa.

The awards were presented during the Axis Annual Partner Awards in a virtual ceremony held on 23 June 2021, as part of Axis Innovates event. The awards celebrated and acknowledged the efforts of Axis' partners by recognizing them for key projects and achievements throughout the year.

"At Axis, we strive to offer solutions of the highest quality. Through our extensive network of Ecosystem Partners, we are able to offer the best solutions addressing the complex and ever–evolving needs of our customers. We are proud of our partnership with SAFR. This award is in appreciation of their support, extensive collaboration, and high quality of their solution offering, combined with aligned business practices and beliefs," said Ettiene Van Der Watt, Regional Director – Middle East and Africa at Axis Communications.

"Axis' worldwide leadership and quality products are a perfect fit for our highly accurate, high–performance facial recognition platform," said Walter Candelu, SAFR' Vice President for the Middle East. "We look forward to furthering our relationship into the future."

About SAFR

SAFR ( is"the world's foremost facial recognition platform for live video intelligence. It taps the power of AI to help the world get back to work. Whether it's used for occupancy counting, face mask detection, or touchless entry control, SAFR can be deployed on premises, in the cloud, or with a VMS. SAFR enhances security, heightens situational awareness, and delivers insights that improve operational efficiency and protect the health and safety of people everywhere.

2021 RealNetworks and SAFR are registered trademarks of RealNetworks, Inc. All other trademarks, names of actual companies, and products mentioned herein are the property of their respective owners.


GLOBENEWSWIRE (Distribution ID 8260337)